Navigation Links
AEterna Zentaris Partner Keryx Presents Phase 1 and Phase 2 Results,for Anti-Cancer Compound Perifosine at ASCO Meeting

e attained an overall 52% CBR which compares favorably with the activity of mTOR inhibitors; - Low dose perifosine (daily and weekly) achieved the same CBR as high dose, including four partial responses; - Toxicities were mainly gastrointestinal and/or fatigue. Low dose perifosine led to substantially less toxicity and decreased early withdrawal from therapy compared to high dose perifosine.

A multi-center Phase 2 trial of low-dose perifosine in sarcomas that generally do not respond to chemotherapy, including chondrosarcoma and myxoid chondrosarcoma, is currently underway through the Sarcoma Alliance for Research through Collaboration (SARC) network.

About Perifosine (KRX-0401)

Perifosine is a novel, first-in-class, oral anti-cancer agent that modulates several key signal transduction pathways, including Akt, MAPK, and JNK that have been shown to be critical for the survival of cancer cells. Perifosine has demonstrated single agent anti-tumor activity in Phase 1 and Phase 2 studies and is currently being studied as a single agent and in combination with several forms of anti-cancer treatments for various forms of cancer. Perifosine (KRX-0401) is licensed to Keryx Biopharmaceuticals in the United States, Canada and Mexico.

About AEterna Zentaris Inc.

AEterna Zentaris Inc. is a global biopharmaceutical company focused on endocrine therapy and oncology with proven expertise in drug discovery, development and commercialization. News releases and additional information are available at www.aeternazentaris.com.

Forward-Looking Statements

This press release contains forward-looking statements made pursuant to the safe harbor provisions of the U.S. Securities Litigation Reform Act of 1995. Statements that are not historical facts, including statements preceded by, followed by, or that include the words "believes", "anticip
'"/>




Page: 1 2 3 4

Related medicine technology :

1. AEterna Zentaris Partner, Spectrum, Discloses Detailed Phase 2 Data for Ozarelix, in BPH at Annual AUA Meeting
2. AEterna Zentaris Discloses In Vivo Data for its GHRH Antagonist JMR-132 at the AACR Annual Meeting in Los Angeles
3. AEterna Zentaris Discloses First In Vitro Data for its PI3K Inhibitors at the AACR Annual Meeting in Los Angeles
4. AEterna Zentaris To Present First In Vitro Data for PI3K Inhibitors and In Vivo Results for a GHRH Antagonist at the AACR Annual Meeting in Los Angeles
5. AEterna Zentaris Reports Positive Results with Cetrorelix in BPH for Japanese Phase 2a Trial
6. terna Zentaris Discloses First In Vitro Data for its PI3K Inhibitors at the AACR Annual Meeting in Los Angeles
7. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
8. GenoLogics Announces Bioinformatics Partnership with Illumina
9. Novelos Therapeutics Announces Encouraging Results in Ongoing Phase 2 Ovarian Cancer Trial at Dana-Farber/Partners Cancer Care
10. Inovio Biomedicals Partners to Present New Data from Two Cancer Immunotherapy Clinical Trials
11. Catalyst Pharmaceutical Partners, Inc. Announces Top-Line Results of Its Bioequivalence Study of CPP-109 (Vigabatrin), the Companys Investigational Drug to Treat Cocaine and Methamphetamine Addiction
Post Your Comments:
(Date:8/21/2014)... , Aug. 21, 2014  eRelevance Corporation ( ... announced today that it has completed integration with ... for Plastic Surgery and Dermatology practices. ... value to healthcare practices using Nextech," stated ... Corporation. "Using information from the EMR we are ...
(Date:8/21/2014)... /CNW/ - Eisai Limited is pleased to support the Canadian ... book available in Canada . The comic ... educate children and their parents about epilepsy, the most common ... than 300,000 Canadians. Eisai is guided by a corporate philosophy ... the patient is central – there was a need within ...
(Date:8/21/2014)... /PRNewswire-iReach/ -- Inc. magazine today ranked ... straight year, No. 349 in Health on its ... the nation,s fastest-growing private companies. The list represents ... segment of the economy—America,s independent entrepreneurs. Companies such ... Zillow, and many other well-known names gained early ...
Breaking Medicine Technology:eRelevance Corporation Integrates with Nextech Electronic Medical Records 2Eisai Pleased to Support Canadian Epilepsy Alliance Comic Book that Teaches Children About Epilepsy 2Carolina's HME Named for Third Straight Year to Inc. Magazine's List of America's Fastest-Growing Private Companies--the Inc. 5000 2Carolina's HME Named for Third Straight Year to Inc. Magazine's List of America's Fastest-Growing Private Companies--the Inc. 5000 3
... DIEGO, Jan. 10, 2011 Optimer Pharmaceuticals, Inc. (Nasdaq: ... Linda Amper, Ph.D., as Senior Vice President of Human ... Economics & Outcomes Research (HEOR), and John Womelsdorf, Ph.D., ... will strengthen the management team as the Company prepares ...
... Calif., Jan. 10, 2011 OncoMed Pharmaceuticals, Inc., ... today announced that patient dosing has commenced in a Phase ... tumor cancers.   OMP-59R5 is a monoclonal antibody ... to specifically block these targets to enter human studies.  The ...
Cached Medicine Technology:Optimer Pharmaceuticals Announces Key Additions to Management Team 2Optimer Pharmaceuticals Announces Key Additions to Management Team 3Optimer Pharmaceuticals Announces Key Additions to Management Team 4OncoMed Pharmaceuticals Initiates Phase 1 Clinical Trial of Anti-Cancer Stem Cell Therapeutic OMP-59R5 2OncoMed Pharmaceuticals Initiates Phase 1 Clinical Trial of Anti-Cancer Stem Cell Therapeutic OMP-59R5 3
(Date:8/22/2014)... patients who need surgery for facial pain caused by ... often used, reports a study in the September issue ... the Congress of Neurological Surgeons . The journal ... a part of Wolters Kluwer Health . , ... much lower cost than other types of surgical treatments ...
(Date:8/22/2014)... August 22, 2014 “Dr. Luciana Show – ... , aka Dr. Luciana, is finding it challenging to stay ... while taking care of hundreds of students, so the editing ... the show is completed, and she recently entered it into ... including those of her husband, actor/screenwriter Gregory Graham , ...
(Date:8/22/2014)... 22, 2014 The report "Higher ... Security & Compliance, Campus Technology, Student & Curriculum, ... (2014-2019)", defines and segments the global Higher Ed ... and forecasting of market sizes. The report also ... and opportunities impacting it along with the adoption ...
(Date:8/22/2014)... However, these are two entirely different mechanisms that occur ... digest lactose properly because they lack an enzyme known ... more dangerous cow milk allergy, however, the body,s immune ... , According to statistics, about two to three percent ... allergy. Less adults are diagnosed with the disease. The ...
(Date:8/22/2014)... August 22, 2014 This funding was ... research affiliate, Saneron CCEL Therapeutics, Inc. in the form ... is extremely pleased to collaborate with Saneron on several ... we hope will lead to regenerative therapies using ... as ALS,” David Portnoy, Chairman and Co-CEO of Cryo-Cell, ...
Breaking Medicine News(10 mins):Health News:More common procedures for painful facial tics carry high costs, reports study in Neurosurgery 2Health News:Professor Luciana Lagana Dedicates to Her CSUN Students the “Dr. Luciana Show-Aging and Falling” AOF Festival Nomination (Screening at Krikorian Monrovia Cinema on 08/25) 2Health News:Professor Luciana Lagana Dedicates to Her CSUN Students the “Dr. Luciana Show-Aging and Falling” AOF Festival Nomination (Screening at Krikorian Monrovia Cinema on 08/25) 3Health News:Professor Luciana Lagana Dedicates to Her CSUN Students the “Dr. Luciana Show-Aging and Falling” AOF Festival Nomination (Screening at Krikorian Monrovia Cinema on 08/25) 4Health News:Higher Education Market Worth $65.83 Billion by 2019 - New Report by MarketsandMarkets 2Health News:Higher Education Market Worth $65.83 Billion by 2019 - New Report by MarketsandMarkets 3Health News:Higher Education Market Worth $65.83 Billion by 2019 - New Report by MarketsandMarkets 4Health News:Scientists uncover why major cow milk allergen is actually allergenic 2Health News:Cryo-Cell Provides Funding for Cord Blood Clinical Trial Application to Treat ALS 2Health News:Cryo-Cell Provides Funding for Cord Blood Clinical Trial Application to Treat ALS 3
... psoriasis condition are more likely to smoke, and smoking contributes ... scaling of the skin, and affect places like legs, scalp, ... of the feet. The chances of people with psoriasis suffering ... published in the Archives of Dermatology. ,Data ...
... Co, known as MSD India, has entered into a collaboration ... studies on the former's investigational cervical cancer drug, Gardasil.// ... India. Under the agreement, clinical trials will be conducted for ... ,The vaccine that has been developed by Merck and ...
... Rutgers, The State University of New Jersey have come ... related to determining the quality of mate in humans.// ... in choosing mates among many animal species. Impressive dancers ... ,Rutgers in association with computer scientist at the University ...
... sitting or lying down is a treatable health problem, but ... ,The condition, called Restless Legs Syndrome (RLS), makes it ... long drives or even while watching a movie, say experts., ... which is accompanied in many cases by a tingling and ...
... Department of Health and Mental Hygiene (DOHMH) has banned at ... "dangerous levels" of lead and mercury. // , ,"Though ... Board of the Institute of Medicine of the National Academies ... ppm (parts per million) of lead and no more than ...
... we took note and took care of mother nature. ... USA.,It is called the Canon National Parks Science Scholars ... eight doctoral students -- from Canada to Chile, and ... are receiving significant multi-year scholarships this year to conduct ...
Cached Medicine News:Health News:Merck, ICMR to conduct joint trials on cervical cancer vaccine 2Health News:Shaking Legs Syndrome Is Curable 2Health News:NY Health Dept Bans 3 Ayurveda Drugs 2Health News:Time to wake up as conservationists 2Health News:Time to wake up as conservationists 3
0.2 mm hook with curved shaft to reach over lens optic. Flat serrated handle with polished finish. Overall length: 4.8 inches. Most popular size or model....
Angled 45 degrees, 10 mm shaft with 0.2 mm tip. Round knurled handle with dull finish. Overall length: 4.6 inches....
Straight 31 mm shaft with flat handle and polished finish. 0.5 mm cup. Overall length: 5 inches....
0.5 mm curette cup, reverse side of sandblasted to polish capsule. Round knurled handle with polished finish. Overall length: 5 inches....
Medicine Products: